Gregg Alton Net Worth

The estimated Net Worth of Gregg H Alton is at least $132 Million dollars as of 12 June 2024. Mr. Alton owns over 6,670 units of Enochian Biosciences Inc stock worth over $7,329 and over the last 19 years he sold ENOB stock worth over $131,460,412. In addition, he makes $82,047 as Independent Director at Enochian Biosciences Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Alton ENOB stock SEC Form 4 insiders trading

Gregg has made over 117 trades of the Enochian Biosciences Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently he exercised 6,670 units of ENOB stock worth $4,669 on 12 June 2024.

The largest trade he's ever made was exercising 120,000 units of Enochian Biosciences Inc stock on 21 January 2014 worth over $2,392,800. On average, Gregg trades about 10,490 units every 31 days since 2005. As of 12 June 2024 he still owns at least 10,470 units of Enochian Biosciences Inc stock.

You can see the complete history of Mr. Alton stock trades at the bottom of the page.

Gregg Alton biography

Gregg H. Alton serves as Independent Director of the Company. Mr. Alton joined the Board after serving for 20 years at the biopharmaceutical company Gilead Sciences, Inc. At Gilead, Mr. Alton served as interim Chief Executive Officer, responsible for the company’s strategy, growth and operations. As Chief Patient Officer, he led Gilead’s patient outreach and engagement initiatives and the company’s efforts to facilitate access to its medicines around the world. He oversaw the corporate and medical affairs functions and developing world access programs, as well as its digital patient solutions and patient-centered outcomes groups and commercial operations in certain countries. Mr. Alton joined Gilead in 1999, and held a number of positions at the company with experience in legal, medical affairs, policy and commercial. He previously served as general counsel. Prior to joining Gilead, he was an attorney at the law firm of Cooley Godward, LLP, where he specialized in mergers and acquisitions, corporate partnerships and corporate finance transactions for healthcare and information technology companies. Mr. Alton is a member of the Board of Directors of Corcept Therapeutics, the Black Women's Health Imperative, and the Boys and Girls Clubs of Oakland. He serves on the U.S. government’s President's Advisory Council on HIV/AIDS, and the advisory boards for UCSF Global Health Group and the UC Berkeley College of Letters & Science. Mr. Alton received a bachelor’s degree in legal studies from the University of California at Berkeley and a law degree from Stanford University.

What is the salary of Gregg Alton?

As the Independent Director of Enochian Biosciences Inc, the total compensation of Gregg Alton at Enochian Biosciences Inc is $82,047. There are 9 executives at Enochian Biosciences Inc getting paid more, with Mark Dybul having the highest compensation of $1,964,450.

How old is Gregg Alton?

Gregg Alton is 54, he's been the Independent Director of Enochian Biosciences Inc since 2019. There are 8 older and 2 younger executives at Enochian Biosciences Inc. The oldest executive at Enochian Biosciences Inc is Carol Brosgart, 69, who is the Independent Director.

What's Gregg Alton's mailing address?

Gregg's mailing address filed with the SEC is 700 QUINCE ORCHARD ROAD, , GAITHERSBURG, MD, 20878.

Insiders trading at Enochian Biosciences Inc

Over the last 7 years, insiders at Enochian Biosciences Inc have traded over $2,106,789 worth of Enochian Biosciences Inc stock and bought 552,919 units worth $3,888,612 . The most active insiders traders include Gregg H Alton, Rene Sindlev, and Serhat Gumrukcu. On average, Enochian Biosciences Inc executives and independent directors trade stock every 91 days with the average trade being worth of $35,881. The most recent stock trade was executed by Serhat Gumrukcu on 18 May 2022, trading 253,493 units of ENOB stock currently worth $2,027,944.

What does Enochian Biosciences Inc do?

enochian biosciences (formerly dandrit biotech usa inc.) a biopharmaceutical company, focuses on the development and commercialization of novel therapies aimed to change the course of immunotherapy treatments for hiv/aids and cancer. the company’s lead candidate eno-1001 (pre-ind) is a potentially sterilizing cure for hiv/aids. eno-2001 is an hiv vaccine in preclinical stage, and its additional compounds eno-4001 (phase three asset), eno-4002, eno-5001, and eno-3001 are in discovery stages for prevention relapse in colon cancer patients. enochian biosciences is headquartered in los angeles, california.

Complete history of Mr. Alton stock trades at Corcept Therapeutics Inc, Gilead Sciences, Novavax, and Enochian Biosciences Inc

Enochian Biosciences Inc executives and stock owners

Enochian Biosciences Inc executives and other stock owners filed with the SEC include:

• Mark Dybul,
  Executive Vice Chairman of the Board, Principal Executive Officer
• Luisa Puche,
  Chief Financial Officer
• Dr. Mark R. Dybul M.D.,
  Chief Exec. Officer & Director
• Luisa Puche,
  Chief Financial Officer
• Evelyn D'An,
  Independent Director
• James Sapirstein,
  Independent Director
• Carl Sandler,
  Independent Director
• Henrik Gronfeldt-Sorensen,
  Director
• Rene Sindlev,
  Independent Chairman of the Board
• Gregg Alton,
  Independent Director
• Carol Brosgart,
  Independent Director
• Dr. François Binette M.Sc., Ph.D.,
  Exec. VP for R&D
• Greg Duczynski Ph.D.,
  Sr. VP for Clinical Operations
• Dr. Serhat Gümrükcü,
  Co-Founder & Inventor
• Tung Nguyen,
  Head of Molecular Biology
• Dr. Wenshi Wang,
  Sr. VP of Operations
• Dr. Serhat Gümrükcü,
  Co-Founder & Inventor
• Francois Binette,
  Executive VP for R&D
• Jayne Mc Nicol,
  Director
• Eric Jean Marie Leire,,
  
• Carl Forest Sandler,
  
• Serhat Gumrukcu,
  10% owner
• Anderson Wittekind William,
  
• Science Llc Weird,